Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)

Coronavirus disease 2019 (COVID-19) causes a hypercoagulable state. Several autopsy studies have found microthrombi in pulmonary circulation. In this randomized, open-label, phase II study, we randomized COVID-19 patients requiring mechanical ventilation to receive either therapeutic enoxaparin or t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Thrombosis research 2020-12, Vol.196, p.359-366
Hauptverfasser:	Lemos, Anna Cristina Bertoldi, do Espírito Santo, Douglas Alexandre, Salvetti, Maísa Cabetti, Gilio, Renato Noffs, Agra, Lucas Barbosa, Pazin-Filho, Antonio, Miranda, Carlos Henrique
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anticoagulant treatment Anticoagulants - administration & dosage Brazil Coagulopathy COVID-19 COVID-19 - complications COVID-19 - diagnosis COVID-19 - drug therapy COVID-19 - physiopathology D-dimer Drug Administration Schedule Enoxaparin - administration & dosage Female Full Length Humans Lung - drug effects Lung - physiopathology Male Mechanical ventilation Middle Aged Pulmonary Gas Exchange - drug effects Respiration, Artificial Thrombophilia - diagnosis Thrombophilia - etiology Thrombophilia - prevention & control Thrombosis - diagnosis Thrombosis - etiology Thrombosis - prevention & control Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!